A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

Abstract Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Current SARS‐CoV‐2 vaccines include mRNA‐containing lipid nanoparticles or adenoviral vectors that encode the SARS‐CoV‐2 Spike (S) protein of SARS‐CoV‐2, inactivated virus, or protein subunits. Despite growing success in worldwide vaccination efforts, additional capabilities may be needed in the future to address issues such as stability and storage requirements, need for vaccine boosters, desirability of different routes of administration, and emergence of SARS‐CoV‐2 variants such as the Delta variant. Here, we present a novel, well‐characterized SARS‐CoV‐2 vaccine candidate based on extracellular vesicles (EVs) of Salmonella typhimurium that are decorated with the mammalian cell culture‐derived Spike receptor‐binding domain (RBD). RBD‐conjugated outer membrane vesicles (RBD‐OMVs) were used to immunize the golden Syrian hamster (Mesocricetus auratus) model of COVID‐19. Intranasal immunization resulted in high titres of blood anti‐RBD IgG as well as detectable mucosal responses. Neutralizing antibody activity against wild‐type and Delta variants was evident in all vaccinated subjects. Upon challenge with live virus, hamsters immunized with RBD‐OMV, but not animals immunized with unconjugated OMVs or a vehicle control, avoided body mass loss, had lower virus titres in bronchoalveolar lavage fluid, and experienced less severe lung pathology. Our results emphasize the value and versatility of OMV‐based vaccine approaches.

[1]  J. Yewdell,et al.  A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters , 2021, Proceedings of the National Academy of Sciences.

[2]  David W. McDonald,et al.  Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[3]  E. van Riet,et al.  An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection , 2021, bioRxiv.

[4]  E. Klein,et al.  Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals , 2021, medRxiv.

[5]  S. Anzick,et al.  Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models , 2021, Science Translational Medicine.

[6]  Xiaozhong Peng,et al.  RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2 , 2021, Nano letters.

[7]  S. Klein,et al.  Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model , 2021, mBio.

[8]  S. Klein,et al.  A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants , 2021, bioRxiv.

[9]  K. Kupferschmidt,et al.  Delta variant triggers new phase in the pandemic , 2021, Science.

[10]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[11]  K. Pienta,et al.  Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single‐particle analysis platforms , 2021, Journal of extracellular vesicles.

[12]  I. Ferlenghi,et al.  Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropriate Methods to Detect Changes in Vaccine Potency , 2021, Vaccines.

[13]  C. Creech,et al.  SARS-CoV-2 Vaccines. , 2021, JAMA.

[14]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[15]  Charles Y. Tan,et al.  A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates , 2020, bioRxiv.

[16]  D. Lauffenburger,et al.  Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters , 2020, Nature medicine.

[17]  Rebecca J. Loomis,et al.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[18]  S. Klein,et al.  Clinical trials for COVID-19 should include sex as a variable. , 2020, The Journal of clinical investigation.

[19]  M. Fowkes,et al.  Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) , 2020, Journal of medical virology.

[20]  Yifan Rao,et al.  The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines , 2020, npj Vaccines.

[21]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[22]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[23]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[24]  H. Frijlink,et al.  Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[25]  W. Jong,et al.  Display of Recombinant Proteins on Bacterial Outer Membrane Vesicles by Using Protein Ligation , 2018, Applied and Environmental Microbiology.

[26]  Aayam Lamichhane,et al.  The mucosal immune system for vaccine development. , 2014, Vaccine.

[27]  M Selim Ünlü,et al.  Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection. , 2014, ACS nano.

[28]  Andrew F. Hill,et al.  Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles , 2014, Journal of extracellular vesicles.

[29]  Tae-Young Roh,et al.  Immunization with Escherichia coli Outer Membrane Vesicles Protects Bacteria-Induced Lethality via Th1 and Th17 Cell Responses , 2013, The Journal of Immunology.

[30]  B. Zakeri,et al.  Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin , 2012, Proceedings of the National Academy of Sciences.

[31]  J. Kim,et al.  Outer Membrane Vesicles Derived from Escherichia coli Induce Systemic Inflammatory Response Syndrome , 2010, PloS one.

[32]  Y. Gho,et al.  Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles. , 2009, Biochimica et biophysica acta.

[33]  R. Deacon Burrowing: A sensitive behavioural assay, tested in five species of laboratory rodents , 2009, Behavioural Brain Research.

[34]  R. Alaniz,et al.  Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo , 2008, The Journal of Immunology.

[35]  R. Alaniz,et al.  Membrane Vesicles Are Immunogenic Facsimiles of Salmonella typhimurium That Potently Activate Dendritic Cells, Prime B and T Cell Responses, and Stimulate Protective Immunity In Vivo1 , 2007, The Journal of Immunology.

[36]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[37]  P. Woo,et al.  Phylogenetic and recombination analysis of coronavirus HKU1, a novel coronavirus from patients with pneumonia , 2005, Archives of Virology.

[38]  R. Lynch,et al.  Differential Induction of Mucosal and Systemic Antibody Responses in Women After Nasal, Rectal, or Vaginal Immunization: Influence of the Menstrual Cycle1 , 2002, The Journal of Immunology.

[39]  J. Holmgren,et al.  Antibody Responses in the Lower Respiratory Tract and Male Urogenital Tract in Humans after Nasal and Oral Vaccination with Cholera Toxin B Subunit , 1999, Infection and Immunity.

[40]  W. Hennink,et al.  Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines. , 2004, Vaccine.